Carl Danzig, MD

Articles by Carl Danzig, MD

Case 3: Treating nAMD in the Presence of Geographic Atrophy

ByArghavan Almony, MD,Adrienne Scott, MD,Roger A. Goldberg, MD, MBA,Carl Danzig, MD

December 13th 2023

Retina experts deliberate on the role of fluorescein angiography in AMD and discuss initiation of anticomplement therapy for geographic atrophy in conjunction with anti-VEGF therapy for neovascular AMD.

Case 3: nAMD in a Patient With Geographic Atrophy

ByArghavan Almony, MD,Adrienne Scott, MD,Roger A. Goldberg, MD, MBA,Carl Danzig, MD

December 13th 2023

Roger Goldberg, MD, presents a case of a patient showing signs of geographic atrophy who subsequently develops nAMD and highlights the favorable outcomes achieved through anti-VEGF therapy.

Approaches to Treating nAMD With PED

ByArghavan Almony, MD,Adrienne Scott, MD,Roger A. Goldberg, MD, MBA,Carl Danzig, MD

December 6th 2023

The expert panel discusses what constitutes treatment failure in anti-VEGF therapy for nAMD and examines how various treatments may yield varying results in managing PED.

Case 2: Treating nAMD With PED

ByArghavan Almony, MD,Adrienne Scott, MD,Roger A. Goldberg, MD, MBA,Carl Danzig, MD

December 6th 2023

Adrienne Scott, MD, presents a case of neovascular AMD with PED in a patient who experiences a stroke while on anti-VEGF therapy.

Approaches to Managing Patients With PDR and DME

ByArghavan Almony, MD,Adrienne Scott, MD,Roger A. Goldberg, MD, MBA,Carl Danzig, MD

November 29th 2023

Expert retina specialists deliberate on their approach to treating DME, emphasizing their primary treatment choice and cases where they would use PRP laser therapy and steroids alongside anti-VEGF treatments.

Case 1: Treatment-naïve Patient with PDR and DME

ByArghavan Almony, MD,Adrienne Scott, MD,Roger A. Goldberg, MD, MBA,Carl Danzig, MD

November 29th 2023

Carl Danzig, MD, presents a case involving a patient with both DME and PDR, showcasing the impressive anatomic improvement achieved by treating with a dual anti-VEGF and Ang2 inhibitor.